✕
Login
Register
EN
Translate page
EN
English
ES
Español
FR
Français
DE
Deutsch
ZH
中文
AR
العربية
PT
Português
RU
Русский
JA
日本語
KO
한국어
HI
हिन्दी
IT
Italiano
Back to News
Ernexa Therapeutics Says ERNA-201 Showed Reduced Disease Severity vs. Untreated Controls In Preliminary Collagen-Induced Arthritis Mouse Study; Pauses ERNA-201 Preclinical Spending To Prioritize ERNA-101 IND Submission In Q4 2026
Benzinga Newsdesk
www.benzinga.com
Positive 92.1%
Neg 0%
Neu 0%
Pos 92.1%
Comments
No comments yet. Be the first!
Join the discussion
Login to comment
Login to comment